IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same

Patent metadata

Field	Value
Publication number	US-10800825-B2
Application number	US-201716329817-A
Country	US
Kind code	B2
Filing date	Aug 31, 2017
Priority date	Sep 2, 2016
Publication date	Oct 13, 2020
Grant date	Oct 13, 2020

Abstract

When the heterodimeric Fc-fused protein according to the present invention is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.

First claim

The invention claimed is:

1. A heterodimeric Fc-fused protein comprising first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to only one of the N-terminus or the C-terminus of the first Fc region or the second Fc region,
wherein CH3 domains of the first Fc region and the second Fc region have a mutation,
wherein the mutation comprises one or more mutations selected from the following (1)-(5);
(1) amino acid residue substitution at position K360 of the CH3 domain of the first Fc region;
(2) amino acid residue substitution at position Q347 of the CH3 domain of the second Fc region;
(3) amino acid residue substitution at position K409 of the CH3 domain of the first Fc region;
(4) amino acid residue substitution at position F405 of the CH3 domain of the second Fc region; and
(5) amino acid residue substitution at position D399 of the CH3 domain of the second Fc region,
wherein amino acid residue numbers are in accordance with EU index.

2. The heterodimeric Fc-fused protein according to claim 1 , wherein the IL-21 is bound to only the N-terminus of the first Fc region or the second Fc region.

3. The heterodimeric Fc-fused protein according to claim 1 , wherein each of the first Fc region and the second Fc region is an Fc region of immunoglobulin selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, and IgE.

4. The heterodimeric Fc-fused protein according to claim 1 , wherein the first Fc region and the second Fc region are included as Fc regions obtained from an immunoglobulin selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, and IgE.

5. The heterodimeric Fc-fused protein according to claim 1 , wherein the mutation of the CH3 domain of the first Fc region or the second Fc region comprises one or more mutations selected from the following (1) (4):
(1) K360E amino acid residue substitution at position K360 of the CH3 domain of the first Fc region;
(2) Q347R amino acid residue substitution at position Q347 of the CH3 domain of the second Fc region;
(3) K409W amino acid residue substitution at position K409 of the CH3 domain of the first Fc region; and
(4) F405T amino acid residue substitution at position F405 of the CH3 domain of the second Fc region and D399V amino acid residue substitution at position D399 of the CH3 domain of the second Fc region,
wherein amino acid residue numbers are in accordance with EU index.

6. A pharmaceutical composition comprising the heterodimeric Fc-fused protein according to claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Univ Korea Res & Bus Found
• Univ Ajou Ind Academic Coop Found

Inventors

• Lee Kyung-Mi
• Lim Seon Ah
• Kim Yong Sung
• Kim Ye Jin

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title

• C07K14/54 Primary

  Interleukins [IL] · CPC title